Biodol Therapeutics develops first-in-class FLT3 inhibitors to treat chronic neuropathic pain by targeting the Receptor Tyrosine Kinase FLT3, which is essential for the onset and persistence of pain. Their compounds enhance opioid efficacy while preventing tolerance, addressing the critical need for safer pain management solutions amid the ongoing opioid crisis.
Funding
$13.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic neuropathic pain is a debilitating condition with limited effective treatments. Existing pain medications, particularly opioids, often lead to tolerance, reduced efficacy, and significant safety risks, contributing to the ongoing opioid crisis. There is a need for novel analgesics that can enhance opioid efficacy while preventing tolerance and reducing the required dosage.
Solution
Biodol Therapeutics is developing first-in-class small molecule inhibitors targeting the Receptor Tyrosine Kinase FLT3 to treat chronic neuropathic pain. The company's compounds inhibit FLT3, a key regulator in triggering and maintaining the chronic neuropathic pain state. By targeting the extracellular domain of FLT3, Biodol's inhibitors reduce pain hypersensitivity and spontaneous pain without affecting normal nervous system functioning. Furthermore, FLT3 inhibition increases the potency of opioids for their analgesic effect and inhibits opioid-induced tolerance, potentially enabling lower and safer opioid doses.
Target Audience
The primary target audience includes individuals suffering from chronic neuropathic pain, as well as physicians and pain specialists seeking safer and more effective pain management solutions.
Features
- FLT3 inhibitors targeting the extracellular domain of the receptor
- Demonstrated reduction of allodynia, pain hypersensitivity, and spontaneous pain in preclinical models
- Potentiation of morphine analgesia and abolishment of morphine-induced tolerance
- Development of both injectable and oral formulations
- Strong IP position with patents covering the use of FLT3 inhibitors for neuropathic pain and in combination with opioids